Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
Recruiting
Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensitivity in muscles and weight loss. The mechanisms underpinning the weight loss caused by GLP-1 agonists have not yet been fully elucidated, but brown adipose tissue (BAT) appears to play an important... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: UCLA Health, Los Angeles, California
Conditions: Obesity